SOURCE: Global Equity Reporter

June 01, 2011 09:00 ET

Stronger Climate Forecasted in Pharmaceuticals -- Insight on Advanced Cell Technology, Inc. and Genmed Holding Corp.

BEIJING--(Marketwire - Jun 1, 2011) - Today, www.GlobalEquityReporter.com announced its research report highlighting Advanced Cell Technology, Inc. (OTCBB: ACTC) and Genmed Holding Corp. (OTCBB: GENM). Full report download is available at www.GlobalEquityReporter.com/access.php.

Biotech is enabling creation of new drugs at a faster pace than the traditional pharmaceutical model and some believe that after a decade of mediocre performance it is approaching an inflection point. Companies are much more conducive to focusing on productivity and the sector is showing signs of being back to top growth by 2013 due to the opportunity emerging markets have created.

Global Equity is reporting on Advanced Cell Technology, Inc. for its position as a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The Company has acquired, developed and maintains a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research. The full report and profile on Advanced Cell Technology, Inc. (OTCBB: ACTC) is available here: www.GlobalEquityReporter.com/get.PDF.1824.php.

Global Equity Reporter brings Genmed Holding Corp. to light for its focus on the sale and distribution of generic drugs. Genmed B.V. maintains a network of manufacturing and distribution relationships in the Netherlands, Belgium, Luxembourg, the United Kingdom, Ireland, Germany and France, as well as some other countries located outside the European Union to supply generic drugs to retail chains. Genmed B.V.'s product is Paracetamol (acetaminophen), a generic form of Tylenol. The full report and profile on Genmed Holding Corp. (OTCBB: GENM) is available here: www.GlobalEquityReporter.com/get.PDF.1937.php.

About Global Equity Reporter
Global Equity Reporter is a premier source for microcap research -- providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers. We report potential market opportunity to our members before the same situation grows to become strong market momentum, enabling our members to see strong market growth by delivering information before the crowd.

Contact Information